AtriCure (ATRC)
Market Price (9/18/2026): $59.08 | Market Cap: $2.9 BilSector: Health Care | Industry: Health Care Equipment
AtriCure (ATRC)
Market Price (9/18/2026): $59.08Market Cap: $2.9 BilSector: Health CareIndustry: Health Care Equipment
Investment Highlights Why It Matters Detailed financial logic regarding cash flow yields vs trend-riding momentum.
Attractive cash flow generationCFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is 11% Low stock price volatilityVol 12M is 46% Megatrend and thematic driversMegatrends include Aging Population & Chronic Disease, Precision Medicine, and Medical Technology Advancement. Themes include Chronic Disease Management, Show more. | Trading close to highsDist 52W High is 0.0%, Dist 3Y High is 0.0% Weak multi-year price returns3Y Excs Rtn is -35% | Expensive valuation multiplesP/EBITPrice/EBIT or Price/(Operating Income) ratio is 162x, P/CFOPrice/(Cash Flow from Operations). CFO is cash before capital expenditures. is 44x, P/EPrice/Earnings or Price/(Net Income) is 273x Stock price has recently run up significantly6M Rtn6 month market price return is 104% Valuation getting more expensiveP/S 6M Chg %Price/Sales change over 6 months. Declining P/S indicates valuation has become less expensive. is 102% Yield minus risk free rate is negativeERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -3.7% Key risksATRC key risks include [1] the competitive threat from less invasive Pulsed Field Ablation (PFA) technologies to its core surgical franchise and [2] a history of unprofitability with projected ongoing losses due to heavy R&D and sales investments. |
| Attractive cash flow generationCFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is 11% |
| Low stock price volatilityVol 12M is 46% |
| Megatrend and thematic driversMegatrends include Aging Population & Chronic Disease, Precision Medicine, and Medical Technology Advancement. Themes include Chronic Disease Management, Show more. |
| Trading close to highsDist 52W High is 0.0%, Dist 3Y High is 0.0% |
| Weak multi-year price returns3Y Excs Rtn is -35% |
| Expensive valuation multiplesP/EBITPrice/EBIT or Price/(Operating Income) ratio is 162x, P/CFOPrice/(Cash Flow from Operations). CFO is cash before capital expenditures. is 44x, P/EPrice/Earnings or Price/(Net Income) is 273x |
| Stock price has recently run up significantly6M Rtn6 month market price return is 104% |
| Valuation getting more expensiveP/S 6M Chg %Price/Sales change over 6 months. Declining P/S indicates valuation has become less expensive. is 102% |
| Yield minus risk free rate is negativeERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -3.7% |
| Key risksATRC key risks include [1] the competitive threat from less invasive Pulsed Field Ablation (PFA) technologies to its core surgical franchise and [2] a history of unprofitability with projected ongoing losses due to heavy R&D and sales investments. |
Qualitative Assessment
AI Analysis | Feedback
AtriCure (ATRC) stock has gained about 115% since 5/31/2026 because of the following key factors:
1. Exceptional Fiscal Q2 2026 Earnings Beat and Raised Full-Year Guidance.
AtriCure reported robust financial results for fiscal Q2 2026, which ended June 30, 2026. The company posted revenue of $153.6 million, exceeding the Zacks Consensus Estimate of $151.5 million by 1.39% and marking a 12.8% year-over-year increase. More notably, AtriCure achieved an Adjusted EPS of $0.18, significantly surpassing the consensus estimate of $0.03, representing a +500% surprise. Profitability also strengthened, with net income reaching $9.0 million and adjusted EBITDA rising by 78% to $27.3 million compared to fiscal Q2 2025. Following this strong performance, management raised its full-year 2026 adjusted EBITDA guidance to a range of $85 million-$89 million, an increase from the previously projected $80 million-$82 million.
2. Robust Performance and Adoption Across Key Product Lines.
The company's revenue growth was primarily fueled by strong adoption and demand across its pain management, appendage management, and open ablation product lines. U.S. revenue in fiscal Q2 2026 grew 13.6% year-over-year to $125.6 million. Specifically, U.S. sales of appendage management products increased by 14.4% to $51.6 million, driven partly by increasing adoption of recently launched devices like the AtriClip FLEX-Mini and PRO-Mini. Open ablation product sales also saw a 12.1% increase, reaching $40.9 million.
Show more
AtriCure (ATRC) stock has gained about 115% since 5/31/2026 because of the following key factors:
1. Exceptional Fiscal Q2 2026 Earnings Beat and Raised Full-Year Guidance.
AtriCure reported robust financial results for fiscal Q2 2026, which ended June 30, 2026. The company posted revenue of $153.6 million, exceeding the Zacks Consensus Estimate of $151.5 million by 1.39% and marking a 12.8% year-over-year increase. More notably, AtriCure achieved an Adjusted EPS of $0.18, significantly surpassing the consensus estimate of $0.03, representing a +500% surprise. Profitability also strengthened, with net income reaching $9.0 million and adjusted EBITDA rising by 78% to $27.3 million compared to fiscal Q2 2025. Following this strong performance, management raised its full-year 2026 adjusted EBITDA guidance to a range of $85 million-$89 million, an increase from the previously projected $80 million-$82 million.
2. Robust Performance and Adoption Across Key Product Lines.
The company's revenue growth was primarily fueled by strong adoption and demand across its pain management, appendage management, and open ablation product lines. U.S. revenue in fiscal Q2 2026 grew 13.6% year-over-year to $125.6 million. Specifically, U.S. sales of appendage management products increased by 14.4% to $51.6 million, driven partly by increasing adoption of recently launched devices like the AtriClip FLEX-Mini and PRO-Mini. Open ablation product sales also saw a 12.1% increase, reaching $40.9 million.
3. Positive Analyst Sentiment and Multiple Price Target Upgrades.
Following the strong fiscal Q2 2026 results and an improved outlook, several Wall Street analysts upgraded their price targets for AtriCure. Needham notably increased its price target to $64 from $45, citing optimism around the BoxX-NoAF trial. Piper Sandler also raised its target to $60 from $50, attributing the change to a new Society of Thoracic Surgeons (STS) quality measure expected to benefit AtriCure's open ablation business. BTIG similarly adjusted its price target upward to $55 from $45, also referencing the new quality metric. This wave of bullish analyst actions contributed to a "Moderate Buy" to "Strong Buy" consensus rating for the stock.
4. Accelerated Progress in Pivotal Clinical Trials.
AtriCure announced significant progress in its key clinical trials, which serve as potential catalysts for future growth and label expansion. The BoxX-NoAF trial, designed to evaluate the efficacy of AtriCure's products in reducing post-operative atrial fibrillation, is reportedly ahead of schedule. The trial has already surpassed 50% enrollment, with over 500 patients, and is on track to complete full enrollment of 960 patients by the end of fiscal year 2026. Data readouts from this trial are anticipated in the first half of fiscal year 2027. The LEAPS trial is also progressing ahead of its enrollment timelines.
Show less
Stock Movement Drivers
Fundamental Drivers
The 113.7% change in ATRC stock from 5/31/2026 to 9/17/2026 was primarily driven by a 108.5% change in the company's P/S Multiple.| (LTM values as of) | 5312026 | 9172026 | Change |
|---|---|---|---|
| Stock Price ($) | 27.67 | 59.12 | 113.7% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 552 | 570 | 3.2% |
| P/S Multiple | 2.4 | 5.1 | 108.5% |
| Shares Outstanding (Mil) | 48 | 49 | -0.7% |
| Cumulative Contribution | 113.7% |
Market Drivers
5/31/2026 to 9/17/2026| Return | Correlation | |
|---|---|---|
| ATRC | 113.7% | |
| Market (SPY) | 0.8% | -0.3% |
| Sector (XLV) | 12.9% | 44.0% |
Fundamental Drivers
The 89.1% change in ATRC stock from 2/28/2026 to 9/17/2026 was primarily driven by a 80.1% change in the company's P/S Multiple.| (LTM values as of) | 2282026 | 9172026 | Change |
|---|---|---|---|
| Stock Price ($) | 31.26 | 59.12 | 89.1% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 535 | 570 | 6.6% |
| P/S Multiple | 2.8 | 5.1 | 80.1% |
| Shares Outstanding (Mil) | 48 | 49 | -1.5% |
| Cumulative Contribution | 89.1% |
Market Drivers
2/28/2026 to 9/17/2026| Return | Correlation | |
|---|---|---|
| ATRC | 89.1% | |
| Market (SPY) | 11.5% | 4.7% |
| Sector (XLV) | 5.8% | 39.5% |
Fundamental Drivers
The 59.8% change in ATRC stock from 8/31/2025 to 9/17/2026 was primarily driven by a 43.1% change in the company's P/S Multiple.| (LTM values as of) | 8312025 | 9172026 | Change |
|---|---|---|---|
| Stock Price ($) | 36.99 | 59.12 | 59.8% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 500 | 570 | 13.9% |
| P/S Multiple | 3.5 | 5.1 | 43.1% |
| Shares Outstanding (Mil) | 48 | 49 | -1.9% |
| Cumulative Contribution | 59.8% |
Market Drivers
8/31/2025 to 9/17/2026| Return | Correlation | |
|---|---|---|
| ATRC | 59.8% | |
| Market (SPY) | 19.2% | 14.6% |
| Sector (XLV) | 24.4% | 29.3% |
Fundamental Drivers
The 30.9% change in ATRC stock from 8/31/2023 to 9/17/2026 was primarily driven by a 55.8% change in the company's Total Revenues ($ Mil).| (LTM values as of) | 8312023 | 9172026 | Change |
|---|---|---|---|
| Stock Price ($) | 45.15 | 59.12 | 30.9% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 366 | 570 | 55.8% |
| P/S Multiple | 5.7 | 5.1 | -11.6% |
| Shares Outstanding (Mil) | 46 | 49 | -4.9% |
| Cumulative Contribution | 30.9% |
Market Drivers
8/31/2023 to 9/17/2026| Return | Correlation | |
|---|---|---|
| ATRC | 30.9% | |
| Market (SPY) | 75.3% | 29.4% |
| Sector (XLV) | 32.7% | 31.3% |
Price Returns Compared
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | Total [1] | |
|---|---|---|---|---|---|---|---|
| Returns | |||||||
| ATRC Return | 25% | -36% | -20% | -14% | 29% | 44% | 3% |
| Peers Return | 18% | -14% | 6% | 10% | 21% | -7% | 34% |
| S&P 500 Return | 27% | -19% | 24% | 23% | 16% | 10% | 101% |
Monthly Win Rates [3] | |||||||
| ATRC Win Rate | 67% | 42% | 58% | 50% | 50% | 44% | |
| Peers Win Rate | 55% | 47% | 52% | 62% | 65% | 49% | |
| S&P 500 Win Rate | 75% | 42% | 67% | 75% | 67% | 44% | |
Max Drawdowns [4] | |||||||
| ATRC Max Drawdown | -27% | -53% | -43% | -47% | -31% | -39% | |
| Peers Max Drawdown | -17% | -30% | -21% | -18% | -13% | -29% | |
| S&P 500 Max Drawdown | -5% | -25% | -10% | -8% | -19% | -9% | |
[1] Cumulative total returns since the beginning of 2021
[2] Peers: MDT, BSX, ABT, JNJ, EW.
[3] Win Rate = % of calendar months in which monthly returns were positive
[4] Max drawdown represents maximum peak-to-trough decline within a year
[5] 2026 data is for the year up to 9/17/2026 (YTD)
How Low Can It Go
| Event | ATRC | S&P 500 |
|---|---|---|
| 2025 US Tariff Shock | ||
| % Loss | -25.5% | -18.8% |
| % Gain to Breakeven | 34.2% | 23.1% |
| Time to Breakeven | 213 days | 79 days |
| Summer-Fall 2023 Five Percent Yield Shock | ||
| % Loss | -38.0% | -9.5% |
| % Gain to Breakeven | 61.2% | 10.5% |
| Time to Breakeven | 1007 days | 24 days |
| 2023 SVB Regional Banking Crisis | ||
| % Loss | -16.8% | -6.7% |
| % Gain to Breakeven | 20.2% | 7.1% |
| Time to Breakeven | 34 days | 31 days |
| 2020 COVID-19 Crash | ||
| % Loss | -41.9% | -33.7% |
| % Gain to Breakeven | 72.2% | 50.9% |
| Time to Breakeven | 43 days | 140 days |
| Q4 2018 Fed Policy Error / Growth Scare | ||
| % Loss | -20.9% | -19.2% |
| % Gain to Breakeven | 26.4% | 23.8% |
| Time to Breakeven | 381 days | 105 days |
| 2015-2016 China Devaluation / Global Growth Scare | ||
| % Loss | -44.5% | -12.2% |
| % Gain to Breakeven | 80.1% | 13.9% |
| Time to Breakeven | 838 days | 62 days |
In The Past
AtriCure's stock fell -25.5% during the 2025 US Tariff Shock. Such a loss loss requires a 34.2% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
| Event | ATRC | S&P 500 |
|---|---|---|
| 2025 US Tariff Shock | ||
| % Loss | -25.5% | -18.8% |
| % Gain to Breakeven | 34.2% | 23.1% |
| Time to Breakeven | 213 days | 79 days |
| Summer-Fall 2023 Five Percent Yield Shock | ||
| % Loss | -38.0% | -9.5% |
| % Gain to Breakeven | 61.2% | 10.5% |
| Time to Breakeven | 1007 days | 24 days |
| 2020 COVID-19 Crash | ||
| % Loss | -41.9% | -33.7% |
| % Gain to Breakeven | 72.2% | 50.9% |
| Time to Breakeven | 43 days | 140 days |
| Q4 2018 Fed Policy Error / Growth Scare | ||
| % Loss | -20.9% | -19.2% |
| % Gain to Breakeven | 26.4% | 23.8% |
| Time to Breakeven | 381 days | 105 days |
| 2015-2016 China Devaluation / Global Growth Scare | ||
| % Loss | -44.5% | -12.2% |
| % Gain to Breakeven | 80.1% | 13.9% |
| Time to Breakeven | 838 days | 62 days |
| 2011 US Debt Ceiling Crisis & European Contagion | ||
| % Loss | -32.7% | -17.9% |
| % Gain to Breakeven | 48.6% | 21.8% |
| Time to Breakeven | 811 days | 123 days |
| 2008-2009 Global Financial Crisis | ||
| % Loss | -91.1% | -53.4% |
| % Gain to Breakeven | 1023.1% | 114.4% |
| Time to Breakeven | 802 days | 1085 days |
In The Past
AtriCure's stock fell -25.5% during the 2025 US Tariff Shock. Such a loss loss requires a 34.2% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
About AtriCure (ATRC)
AtriCure, Inc. (ATRC) is a medical device company specializing in developing, manufacturing, and selling innovative solutions primarily for the surgical treatment of cardiac arrhythmias, such as atrial fibrillation, and nerve pain. The company focuses on devices that perform ablation of cardiac tissue and intercostal nerves, aiming to improve patient outcomes in complex surgical procedures.
AtriCure's product portfolio is diverse, offering a range of tools for surgeons. Key cardiac ablation products include the Isolator Synergy Clamps and multifunctional pens like the MAX Pen, which allow for tissue ablation, pacing, and sensing. They also offer the cryoICE Cryoablation System and the EPi-Sense Guided Coagulation System, specifically designed for treating persistent atrial fibrillation. Beyond ablation, AtriCure provides solutions for left atrial appendage management with the AtriClip System and LARIAT System, which are used to prevent stroke risk associated with atrial fibrillation.
AtriCure serves medical centers globally, with a significant presence in the United States, Europe, and Asia. The company distributes its products through both independent distributors and a direct sales force, ensuring reach to a broad network of cardiac and thoracic surgeons. Their devices are critical tools used during surgical procedures for heart valve repair or replacement, as well as dedicated arrhythmia treatment, addressing a wide range of patient needs in advanced cardiac care.
AI Analysis | Feedback
Here are a few brief analogies for AtriCure:
A focused Medtronic specializing in surgical devices for cardiac arrhythmias.
The Boston Scientific of surgical heart solutions, particularly for atrial fibrillation.
AI Analysis | Feedback
- Isolator Synergy Clamps: Single-use disposable radio frequency products for surgical cardiac tissue ablation.
- MAX Pen device: A multifunctional pen for evaluating cardiac arrhythmias, temporary cardiac pacing, sensing, stimulation, and ablating cardiac tissue.
- Coolrail device: Enables users to make longer linear lines of ablation.
- cryoICE Cryoablation System: A system that enables linear ablations of varied lengths using cryoablation.
- EPi-Sense Guided Coagulation System: A single-use disposable device for the treatment of symptomatic, drug-refractory, and long-standing persistent atrial fibrillation.
- AtriClip System: An implantable device coupled to a single-use disposable applier for left atrial appendage management.
- LARIAT System: A suture-based solution for soft-tissue closure.
- Lumitip Dissectors: Instruments used to separate tissues to provide access to key anatomical structures targeted for ablation.
- Glidepath guides: Guides for the accurate placement of clamps during surgical procedures.
- Subtle Cannula's: Cannulas that support access for EPi-Sense catheters.
- Reusable cardiac surgery instruments: Various instruments used during surgical procedures for heart valve repair or replacement.
AI Analysis | Feedback
AtriCure (ATRC) sells primarily to other organizations. Its major customers are medical centers, which encompass institutions such as hospitals, surgical centers, and clinics. While the company sells to these types of organizations, the provided background information does not list the names of specific medical center chains or distributor companies that are major customers, nor does it provide their public symbols.
AI Analysis | Feedback
AI Analysis | Feedback
Michael H. Carrel, President and Chief Executive Officer
Mr. Carrel has served as President, Chief Executive Officer, and director of AtriCure since November 2012. Before joining AtriCure, he was President and Chief Executive Officer of Vital Images, Inc., a publicly-traded medical imaging software company that was acquired by Toshiba Medical Systems Corporation in 2011. Prior to Vital Images, Mr. Carrel was President and CEO of Zamba Corporation, a publicly-traded technology company, and Chief Financial Officer of NextNet Wireless, Inc., a privately-held provider of broadband wireless access systems, both of which had successful acquisition exits. He currently serves as Board Chair of Axonics, Inc., a publicly-traded medical device company that recently announced an agreement to be acquired by Boston Scientific. During his tenure at AtriCure, the company has acquired three companies: Estech, nContact, and SentreHEART.
Angela L. Wirick, Chief Financial Officer
Ms. Wirick was appointed Chief Financial Officer in August 2020. She previously served as AtriCure's Vice President, Finance for four years and joined the company in 2014 as Director, Finance. Ms. Wirick began her career in public accounting at Arthur Andersen LLP and Deloitte & Touche LLP, serving clients in various industries. She is a Certified Public Accountant (Inactive).
Douglas J. Seith, Chief Operating Officer
Mr. Seith has served as Chief Operating Officer of AtriCure since January 2015. He previously held roles within AtriCure as Senior Vice President, Sales and Marketing from 2013 to 2014, and Vice President, United States Sales from 2011 to 2013. He joined AtriCure in 2004 as a Regional Sales Leader. Prior to AtriCure, Mr. Seith held sales leadership and sales positions at A-Med/EmoblX, Inc., Heartport, Inc., Scimed Life Systems (a division of Boston Scientific, Inc.), and Automated Instruments.
Justin Noznesky, Chief Marketing and Strategy Officer
Mr. Noznesky has served as Chief Marketing and Strategy Officer since March 2021. He previously held leadership positions at AtriCure as Senior Vice President, Marketing and Business Development since March 2016, and Vice President, Marketing and Business Development since January 2014. From 2004 to 2013, he held various leadership positions at Vital Images, Inc., a subsidiary of Toshiba Medical Systems Corporation. Before Vital Images, Mr. Noznesky worked in Corporate Finance at UnitedHealth Group and as a senior auditor at Arthur Andersen LLP.
Karl Dahlquist, Chief Legal Officer
Mr. Dahlquist has served as Chief Legal Officer since March 2019. He joined AtriCure in August 2013 as Vice President, Legal and Regulatory Affairs and Chief Compliance Officer. Mr. Dahlquist began his career as a lawyer specializing in medical device litigation and regulation. His previous experience includes senior legal, compliance, and quality management roles at Medtronic, Inc., St. Jude Medical, GE Healthcare, and Johnson & Johnson.
AI Analysis | Feedback
Key Risks to AtriCure (ATRC)
-
Competitive Pressure and Technological Disruption
The medical device industry for cardiac care is highly competitive, and AtriCure faces significant pressure from evolving technologies, particularly the rapid adoption of Pulsed Field Ablation (PFA) catheter technologies. These less invasive alternatives to AtriCure's surgical tools have created a direct operational challenge, leading to declines in revenue within the company's U.S. hybrid therapy and minimally invasive ablation franchises. While AtriCure is developing its own PFA platforms, the ongoing shift in market preference presents a material risk to sustaining U.S. revenue and margins. -
Regulatory and Reimbursement Challenges
AtriCure operates in a highly regulated environment, and the timing of new product regulatory clearances, such as those from the FDA, and subsequent third-party payer reimbursement are uncertain. Delays or unfavorable changes in these areas can directly impact sales forecasts and market access. International markets also present reimbursement risks, with reported declines in sales in regions like the UK due to funding and reimbursement uncertainties with the National Health Service. The company has also faced past allegations and settlements related to off-label marketing and incorrect billing practices for Medicare reimbursement, highlighting the stringent regulatory scrutiny. -
Profitability Challenges
Despite strong revenue growth, AtriCure has historically faced challenges in achieving consistent profitability on a GAAP basis, reporting net losses in previous years and anticipating continued unprofitability due to significant investments in research and development (R&D) for new products and clinical trials. While there are signs of improving operating and net margins in recent quarters, maintaining this trend and achieving sustained profitability remains a critical financial risk for the company.
AI Analysis | Feedback
The emergence of Pulsed Field Ablation (PFA) technology poses a clear emerging threat. PFA is a non-thermal cardiac ablation technology that delivers high-voltage, short-duration electrical pulses to create irreversible electroporation, selectively targeting cardiac tissue while potentially minimizing damage to surrounding structures like the esophagus and phrenic nerve. As PFA gains broader adoption, especially in catheter-based procedures for conditions like atrial fibrillation which AtriCure's surgical thermal ablation devices address, it could disrupt the market for traditional surgical radiofrequency (RF) and cryoablation devices by offering a potentially safer and equally effective alternative.
AI Analysis | Feedback
AtriCure (ATRC) operates in significant addressable markets for its primary products, focusing on the treatment of atrial fibrillation (AFib) and left atrial appendage (LAA) management.
Atrial Fibrillation (AFib) Ablation Devices Market
- AtriCure estimates the global market for the treatment of atrial fibrillation to be approximately $5 billion, with surgical and minimally invasive surgery comprising about 75% of this market, and postoperative pain management accounting for the remaining 25%.
- The global cardiac ablation devices market, which addresses conditions like AFib, atrial flutter, and atrial tachycardia, was valued at approximately $3.07 billion in 2023 and is projected to reach about $5.42 billion by 2028, demonstrating a compound annual growth rate (CAGR) of 12.0%.
- Other estimates indicate the global cardiac ablation market was valued at USD 5.8 billion in 2025 and is projected to grow to USD 20 billion by 2035, expanding at a CAGR of 12.8%.
- The broader global atrial fibrillation devices market was valued at USD 12.9 billion in 2025 and is expected to reach USD 40.2 billion by 2035, with a CAGR of 12.2%. This market encompasses various devices, including EP ablation catheters and LAA closure devices.
- In North America, the cardiac ablation market was valued at USD 2.3 billion in 2025. The atrial fibrillation devices market in North America reached USD 4.9 billion in 2025.
- AtriCure holds a significant position in this sector, commanding an estimated 60% market share in surgical AFib ablation.
Left Atrial Appendage (LAA) Closure Devices Market
This market is relevant for AtriCure's AtriClip System and the LARIAT System when used for LAA management.
- The global left atrial appendage closure devices market was valued at approximately USD 1.87 billion in 2024 and is projected to grow to around USD 7.01 billion by 2034, at a CAGR of 14.12%.
- Other estimates for the global market in 2024 range from USD 1.7 billion to USD 1.8 billion. Projections for this market vary, with some reaching USD 5.7 billion by 2030 and others up to USD 6.7 billion by 2033.
- North America is a dominant region in this market, holding the largest market share of 46.2% in 2024. The left atrial appendage closure devices market size in North America reached USD 720 million in 2023. The U.S. market specifically was valued at USD 803.9 million in 2024.
AI Analysis | Feedback
- Continued Adoption and Launch of Innovative Products: AtriCure anticipates significant revenue growth driven by the continued adoption of recently launched products and the introduction of new devices. Specifically, the AtriClip PRO Mini, cryoXT PRO, cryoSPHERE MAX, and cryoSPHERE Plus probes are highlighted as key contributors to revenue growth. The EnCompass Clamp has also been a significant growth driver, with increased account penetration and mid-teens growth over 2024. These new and recently launched products are expected to drive top-line expansion by increasing both volumes and average selling prices.
- Growth in the Pain Management Franchise: The pain management franchise is consistently identified as a strong growth area and is expected to lead AtriCure's growth in 2026. This growth is supported by newer products like the cryoSPHERE MAX and Plus probes, and the low penetration in thoracic procedures, along with a newer opportunity related to amputations.
- International Market Expansion: AtriCure projects strong momentum in its international business, with healthy adoption across key product lines and markets. International revenue saw a substantial increase in 2025, particularly in Europe and Asia Pacific. A significant step in this expansion was the approval in July 2024 for the AtriClip LAA Exclusion System in China, opening access to a large market.
- Clinical Trial Progress and Market Expansion for Existing Therapies: Progress in clinical trials like LeAAPS (evaluating AtriClip devices) and BoxX-NoAF (to reduce postoperative Afib) is expected to drive momentum and enhance product adoption. Furthermore, continued adoption of the EnCompass clamp in open ablation, especially in areas like coronary artery bypass grafting (CABG) where penetration was historically low, is broadening the addressable market for AtriCure's open cardiac surgery tools.
AI Analysis | Feedback
Share Repurchases
- In 2025, net cash used in financing activities increased by $3,882 due to shares repurchased for the payment of taxes.
Share Issuance
- Total shares outstanding have steadily increased, rising from 48.9 million at the end of a recent fiscal year to 49.7 million in Q4 2025, primarily due to stock-based compensation programs.
- In March 2026, the Chief Operating Officer received 42,386 shares as a restricted stock award and acquired 25,532 shares from a performance share award.
- Also in March 2026, the Chief Technical Officer acquired 30,390 shares through a Restricted Stock Award and 15,198 shares from a Performance Share Award.
Inbound Investments
- AtriCure maintained a strong liquidity position, with cash and cash equivalents totaling $167.4 million as of December 31, 2025.
- The company has a $125 million asset-based revolving credit facility with JPMorgan Chase Bank, with an option to increase by $40 million, which was recently amended to extend the term and reduce the overall interest rate.
- A sale-and-leaseback transaction generated $6.25 million in cash proceeds.
Outbound Investments
- Long-Term Investments were $7.6 million in 2023, marking a significant decrease from $51.51 million in 2022 and $104.34 million in 2021.
- Net cash used in investing activities increased by approximately $49.9 million from 2024 to 2025, influenced by a decrease in sales and maturities of available-for-sale securities, and a $5 million payment for an acquired IPR&D milestone.
Capital Expenditures
- Capital expenditures were reported at $1.6 million in Q4 2025.
- AtriCure operates a capital-light model, requiring very low capital expenditure needs, which allows strong revenue growth to translate into robust free cash flow.
- The company remains committed to funding key research and development (R&D) initiatives to support innovation and growth.
Peer Outperformance in Health Care Equipment
| Ticker | Name | Rev Growth 3Y Avg | P/E | 1Y | 3Y | 5Y | 5Y Gap |
|---|---|---|---|---|---|---|---|
| ATRC | AtriCure | 15.9% | 272.7x | 68.9% | 36.0% | -22.9% | — |
| UFPT | UFP Technologies | 18.8% | 29.5x | 34.4% | 72.0% | 334.1% | +357pp |
| Industry | Names | 1Y med | 3Y med | 5Y med | Top 3 by 5Y |
|---|---|---|---|---|---|
| Health Care Distributors | 7 | 7.8% | 77.2% | 101.1% | CAH 380% · MCK 334% · COR 164% |
| Managed Health Care | 8 | 40.9% | -1.4% | 1.5% | OSCR 83% · HQY 48% · ELV 17% |
| Health Care Services | 20 | 25.4% | 42.2% | -1.8% | HIMS 219% · RDNT 172% · DGX 76% |
| Health Care Facilities | 24 | 5.6% | 0.8% | -12.7% | NHC 274% · THC 259% · ENSG 127% |
| Health Care Equipment ← | 50 | -0.8% | -4.9% | -21.9% | POCI 10800% · UFPT 334% · GKOS 199% |
| Pharmaceuticals | 62 | -5.1% | 12.4% | -39.8% | LQDA 2442% · INDV 1175% · ETON 1012% |
| Health Care Supplies | 12 | 17.1% | -12.2% | -40.3% | LNTH 294% · HAE 53% · MMSI 19% |
| Life Sciences Tools & Services | 109 | 5.4% | -22.1% | -68.8% | SNWV 1586% · MEDP 231% · NTRA 190% |
| Health Care Technology | 21 | -25.5% | -51.1% | -79.7% | SPOK 72% · HSTM 1% · VEEV -13% |
| Biotechnology | 364 | 0.4% | -26.6% | -79.8% | DNTH 1198% · CELZ 1154% · ELVN 1077% |
Latest Trefis Analyses
| Title | |
|---|---|
| ARTICLES |
Research & Analysis
Invest in Strategies
Wealth Management
Peer Comparisons
| Peers to compare with: |
Financials
| Median | |
|---|---|
| Name | |
| Mkt Price | 90.51 |
| Mkt Cap | 91.4 |
| Rev LTM | 29,268 |
| Op Inc LTM | 5,778 |
| FCF LTM | 3,969 |
| FCF 3Y Avg | 3,875 |
| CFO LTM | 6,282 |
| CFO 3Y Avg | 5,588 |
Growth & Margins
| Median | |
|---|---|
| Name | |
| Rev Chg LTM | 11.6% |
| Rev Chg 3Y Avg | 9.6% |
| Rev Chg Q | 12.9% |
| QoQ Delta Rev Chg LTM | 3.2% |
| Op Inc Chg LTM | 18.3% |
| Op Inc Chg 3Y Avg | 7.2% |
| Op Mgn LTM | 20.0% |
| Op Mgn 3Y Avg | 18.8% |
| QoQ Delta Op Mgn LTM | 0.4% |
| CFO/Rev LTM | 21.5% |
| CFO/Rev 3Y Avg | 20.6% |
| FCF/Rev LTM | 16.6% |
| FCF/Rev 3Y Avg | 14.9% |
Price Behavior
| Market Price | $59.12 | |
| Market Cap ($ Bil) | 2.9 | |
| First Trading Date | 08/05/2005 | |
| Distance from 52W High | 0.0% | |
| 50 Days | 200 Days | |
| DMA Price | $43.97 | $35.19 |
| DMA Trend | up | up |
| Distance from DMA | 34.4% | 68.0% |
| 3M | 1YR | |
| Volatility | 45.5% | 45.9% |
| Downside Capture | -226.62 | 51.90 |
| Upside Capture | 182.33 | 103.57 |
| Correlation (SPY) | -7.9% | 14.2% |
| 1M | 2M | 3M | 6M | 1Y | 3Y | |
|---|---|---|---|---|---|---|
| Beta | 0.59 | -0.15 | -0.17 | 0.11 | 0.54 | 0.93 |
| Up Beta | 0.26 | -1.89 | -1.39 | -0.54 | -0.14 | 0.99 |
| Down Beta | -0.40 | 0.32 | 0.79 | 0.46 | 0.37 | 0.85 |
| Up Capture | 268% | 246% | 122% | 64% | 88% | 62% |
| Bmk +ve Days | 10 | 21 | 32 | 68 | 138 | 427 |
| Stock +ve Days | 15 | 27 | 36 | 65 | 126 | 375 |
| Down Capture | -243% | -227% | -200% | -35% | 82% | 101% |
| Bmk -ve Days | 11 | 21 | 32 | 59 | 113 | 324 |
| Stock -ve Days | 6 | 15 | 26 | 60 | 123 | 371 |
[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
Based On 1-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with ATRC | |
|---|---|---|---|---|
| ATRC | 64.7% | 45.9% | 1.22 | - |
| Sector ETF (XLV) | 25.0% | 16.1% | 1.19 | 27.2% |
| Equity (SPY) | 16.6% | 12.9% | 0.92 | 14.5% |
| Gold (GLD) | 17.4% | 29.3% | 0.55 | 7.4% |
| Commodities (DBC) | 45.8% | 20.7% | 1.72 | -13.3% |
| Real Estate (VNQ) | 5.7% | 13.5% | 0.16 | 26.7% |
| Bitcoin (BTCUSD) | -34.9% | 43.9% | -0.85 | 16.3% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 5-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with ATRC | |
|---|---|---|---|---|
| ATRC | -5.1% | 47.7% | 0.05 | - |
| Sector ETF (XLV) | 6.3% | 15.2% | 0.23 | 36.9% |
| Equity (SPY) | 12.6% | 17.2% | 0.56 | 40.9% |
| Gold (GLD) | 18.9% | 18.8% | 0.81 | 7.1% |
| Commodities (DBC) | 11.7% | 19.6% | 0.47 | 2.7% |
| Real Estate (VNQ) | 1.0% | 18.8% | -0.05 | 39.5% |
| Bitcoin (BTCUSD) | 10.4% | 52.5% | 0.38 | 22.7% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 10-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with ATRC | |
|---|---|---|---|---|
| ATRC | 13.1% | 44.0% | 0.43 | - |
| Sector ETF (XLV) | 10.6% | 16.7% | 0.51 | 38.9% |
| Equity (SPY) | 15.1% | 18.0% | 0.71 | 42.9% |
| Gold (GLD) | 12.0% | 16.4% | 0.60 | 5.3% |
| Commodities (DBC) | 8.5% | 18.1% | 0.39 | 10.6% |
| Real Estate (VNQ) | 4.4% | 20.7% | 0.17 | 37.4% |
| Bitcoin (BTCUSD) | 62.0% | 66.1% | 1.02 | 15.0% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Returns Analyses
Earnings Returns History
Updated 8/25/2026| Forward Returns | |||
|---|---|---|---|
| Earnings Date | 1D Returns | 5D Returns | 21D Returns |
| 7/23/2026 | 6.2% | 21.7% | 48.4% |
| 5/5/2026 | -4.7% | -9.2% | -7.2% |
| 2/17/2026 | -2.2% | -5.6% | -12.5% |
| 10/29/2025 | -3.8% | -8.8% | -1.0% |
| 7/29/2025 | 10.7% | 18.3% | 17.6% |
| 4/29/2025 | -13.7% | -13.9% | -1.6% |
| 2/12/2025 | -6.5% | -7.6% | -21.4% |
| 10/29/2024 | 18.3% | 20.5% | 22.9% |
| ... | |||
| SUMMARY STATS | |||
| # Positive | 11 | 10 | 10 |
| # Negative | 13 | 14 | 14 |
| Median Positive | 8.3% | 8.1% | 14.4% |
| Median Negative | -3.8% | -6.6% | -7.8% |
| Max Positive | 18.3% | 21.7% | 48.4% |
| Max Negative | -13.7% | -25.9% | -21.4% |
| Forward Returns | |||
|---|---|---|---|
| Earnings Date | 1D Returns | 5D Returns | 21D Returns |
| 7/23/2026 | 6.2% | 21.7% | 48.4% |
| 5/5/2026 | -4.7% | -9.2% | -7.2% |
| 2/17/2026 | -2.2% | -5.6% | -12.5% |
| 10/29/2025 | -3.8% | -8.8% | -1.0% |
| 7/29/2025 | 10.7% | 18.3% | 17.6% |
| 4/29/2025 | -13.7% | -13.9% | -1.6% |
| 2/12/2025 | -6.5% | -7.6% | -21.4% |
| 10/29/2024 | 18.3% | 20.5% | 22.9% |
| 7/30/2024 | -2.0% | -2.0% | 16.4% |
| 5/1/2024 | -10.3% | -16.4% | -9.0% |
| 2/15/2024 | -4.4% | -1.9% | -6.6% |
| 11/1/2023 | 4.5% | 5.8% | 4.5% |
| 7/25/2023 | 8.5% | 5.8% | -11.7% |
| 5/2/2023 | 10.0% | 9.1% | 4.2% |
| 2/21/2023 | 8.3% | -1.9% | -1.2% |
| 11/1/2022 | -6.0% | -5.4% | 7.0% |
| 8/2/2022 | -0.6% | -1.5% | -8.2% |
| 5/3/2022 | -2.4% | -25.9% | -21.3% |
| 2/15/2022 | 3.7% | -4.7% | 0.1% |
| 11/3/2021 | 8.9% | 0.1% | -16.9% |
| 8/4/2021 | -0.5% | -11.9% | -7.4% |
| 4/27/2021 | 7.6% | 19.1% | 12.4% |
| 2/23/2021 | 0.3% | 7.2% | -1.6% |
| 11/5/2020 | -1.1% | 5.0% | 22.2% |
| SUMMARY STATS | |||
| # Positive | 11 | 10 | 10 |
| # Negative | 13 | 14 | 14 |
| Median Positive | 8.3% | 8.1% | 14.4% |
| Median Negative | -3.8% | -6.6% | -7.8% |
| Max Positive | 18.3% | 21.7% | 48.4% |
| Max Negative | -13.7% | -25.9% | -21.4% |
SEC Filings
Expand for More| Report Date | Filing Date | Filing |
|---|---|---|
| 06/30/2026 | 07/27/2026 | 10-Q |
| 03/31/2026 | 05/06/2026 | 10-Q |
| 12/31/2025 | 02/19/2026 | 10-K |
| 09/30/2025 | 10/30/2025 | 10-Q |
| 06/30/2025 | 07/30/2025 | 10-Q |
| 03/31/2025 | 04/30/2025 | 10-Q |
| 12/31/2024 | 02/14/2025 | 10-K |
| 09/30/2024 | 10/30/2024 | 10-Q |
| 06/30/2024 | 07/31/2024 | 10-Q |
| 03/31/2024 | 05/02/2024 | 10-Q |
| 12/31/2023 | 02/16/2024 | 10-K |
| 09/30/2023 | 11/02/2023 | 10-Q |
| 06/30/2023 | 07/26/2023 | 10-Q |
| 03/31/2023 | 05/03/2023 | 10-Q |
| 12/31/2022 | 02/22/2023 | 10-K |
| 09/30/2022 | 11/02/2022 | 10-Q |
| Report Date | Filing Date | Filing |
|---|---|---|
| 06/30/2026 | 07/27/2026 | 10-Q |
| 03/31/2026 | 05/06/2026 | 10-Q |
| 12/31/2025 | 02/19/2026 | 10-K |
| 09/30/2025 | 10/30/2025 | 10-Q |
| 06/30/2025 | 07/30/2025 | 10-Q |
| 03/31/2025 | 04/30/2025 | 10-Q |
| 12/31/2024 | 02/14/2025 | 10-K |
| 09/30/2024 | 10/30/2024 | 10-Q |
| 06/30/2024 | 07/31/2024 | 10-Q |
| 03/31/2024 | 05/02/2024 | 10-Q |
| 12/31/2023 | 02/16/2024 | 10-K |
| 09/30/2023 | 11/02/2023 | 10-Q |
| 06/30/2023 | 07/26/2023 | 10-Q |
| 03/31/2023 | 05/03/2023 | 10-Q |
| 12/31/2022 | 02/22/2023 | 10-K |
| 09/30/2022 | 11/02/2022 | 10-Q |
| 06/30/2022 | 08/03/2022 | 10-Q |
| 03/31/2022 | 05/04/2022 | 10-Q |
| 12/31/2021 | 02/17/2022 | 10-K |
| 09/30/2021 | 11/04/2021 | 10-Q |
| 06/30/2021 | 08/05/2021 | 10-Q |
| 03/31/2021 | 04/28/2021 | 10-Q |
| 12/31/2020 | 02/26/2021 | 10-K |
| 09/30/2020 | 11/06/2020 | 10-Q |
| 06/30/2020 | 07/29/2020 | 10-Q |
| 03/31/2020 | 04/30/2020 | 10-Q |
| 12/31/2019 | 02/24/2020 | 10-K |
| 09/30/2019 | 10/31/2019 | 10-Q |
Recent Forward Guidance
Updated 7/27/2026Latest: Q2 2026 Earnings Reported 7/23/2026
| Forward Guidance | Guidance Change | |||||||
|---|---|---|---|---|---|---|---|---|
| Metric | Source | Low | Mid | High | % Chg | % Delta | Change | Prior |
| 2026 Revenue | Reported | 602.00 Mil | 606.00 Mil | 610.00 Mil | 0.2% | Raised | Guidance: 605.00 Mil for 2026 | |
| 2026 Adjusted EBITDA | Reported | 85.00 Mil | 87.00 Mil | 89.00 Mil | 7.4% | Raised | Guidance: 81.00 Mil for 2026 | |
| 2026 Net Income Per Share | Reported | 0.05 | 0.09 | 0.13 | ||||
| 2026 Adjusted Earnings Per Share | Reported | 0.24 | 0.28 | 0.32 | 1300.0% | Raised | Guidance: 0.02 for 2026 | |
Prior: Q1 2026 Earnings Reported 5/5/2026
| Forward Guidance | Guidance Change | |||||||
|---|---|---|---|---|---|---|---|---|
| Metric | Source | Low | Mid | High | % Chg | % Delta | Change | Prior |
| 2026 Revenue | Reported | 600.00 Mil | 605.00 Mil | 610.00 Mil | 0 | Affirmed | Guidance: 605.00 Mil for 2026 | |
| 2026 Adjusted EBITDA | Reported | 80.00 Mil | 81.00 Mil | 82.00 Mil | 0 | Affirmed | Guidance: 81.00 Mil for 2026 | |
| 2026 Adjusted EPS | Reported | 0 | 0.02 | 0.04 | -83.3% | Lowered | Guidance: 0.12 for 2026 | |
Q4 2025 Earnings Reported 2/17/2026
| Forward Guidance | Guidance Change | |||||||
|---|---|---|---|---|---|---|---|---|
| Metric | Source | Low | Mid | High | % Chg | % Delta | Change | Prior |
| 2026 Revenue | Reported | 600.00 Mil | 605.00 Mil | 610.00 Mil | 13.5% | Higher New | Actual: 533.00 Mil for 2025 | |
| 2026 Revenue Growth | Reported | 12.0% | 13.0% | 14.0% | ||||
| 2026 Adjusted EBITDA | Reported | 80.00 Mil | 81.00 Mil | 82.00 Mil | 44.6% | Higher New | Actual: 56.00 Mil for 2025 | |
| 2026 Adjusted EPS | Reported | 0.09 | 0.12 | 0.15 | Higher New | Actual: -0.24 for 2025 | ||
| 2026 Net EPS | Reported | 0 | 0.02 | 0.04 | ||||
Q3 2025 Earnings Reported 10/29/2025
| Forward Guidance | Guidance Change | |||||||
|---|---|---|---|---|---|---|---|---|
| Metric | Source | Low | Mid | High | % Chg | % Delta | Change | Prior |
| 2025 Adjusted Loss Per Share | Reported | -0.26 | -0.24 | -0.23 | -32.9% | Raised | Guidance: -0.36 for 2025 | |
| 2025 Revenue | Reported | 532.00 Mil | 533.00 Mil | 534.00 Mil | 0.6% | Raised | Guidance: 530.00 Mil for 2025 | |
| 2025 Adjusted EBITDA | Reported | 55.00 Mil | 56.00 Mil | 57.00 Mil | 10.9% | Raised | Guidance: 50.50 Mil for 2025 | |
Insider Activity
Updated 9/14/2026| # | Owner | Title | Holding | Action | Filing Date | Price | Shares | Transacted Value | Value of Held Shares | Form |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Groves, Regina E | Direct | Sell | 9142026 | 54.22 | 5,313 | 288,071 | 1,873,084 | Form | |
| 2 | Privitera, Salvatore | Chief Technical Officer | Direct | Sell | 9102026 | 55.00 | 3,657 | 201,135 | 8,099,520 | Form |
| 3 | Privitera, Salvatore | Chief Technical Officer | Direct | Sell | 9042026 | 52.50 | 7,763 | 407,558 | 7,923,352 | Form |
| 4 | Dahlquist, Karl S | Chief Legal Officer | Direct | Sell | 8262026 | 48.89 | 9,370 | 458,099 | 4,269,026 | Form |
| 5 | Yuen, Maggie | Direct | Sell | 8072026 | 38.42 | 3,500 | 134,470 | 538,456 | Form |
| # | Owner | Title | Holding | Action | Filing Date | Price | Shares | Transacted Value | Value of Held Shares | Form |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Groves, Regina E | Direct | Sell | 9142026 | 54.22 | 5,313 | 288,071 | 1,873,084 | Form | |
| 2 | Privitera, Salvatore | Chief Technical Officer | Direct | Sell | 9102026 | 55.00 | 3,657 | 201,135 | 8,099,520 | Form |
| 3 | Privitera, Salvatore | Chief Technical Officer | Direct | Sell | 9042026 | 52.50 | 7,763 | 407,558 | 7,923,352 | Form |
| 4 | Dahlquist, Karl S | Chief Legal Officer | Direct | Sell | 8262026 | 48.89 | 9,370 | 458,099 | 4,269,026 | Form |
| 5 | Yuen, Maggie | Direct | Sell | 8072026 | 38.42 | 3,500 | 134,470 | 538,456 | Form | |
| 6 | Prange, Karen | Direct | Sell | 8072026 | 38.80 | 3,564 | 138,283 | 884,989 | Form | |
| 7 | Noznesky, Justin J | Chief Mktg & Strategy Officer | Direct | Sell | 7302026 | 38.80 | 6,182 | 239,862 | 3,888,497 | Form |
| 8 | Doraiswamy, Vinayak | Chief Scientific Officer | Direct | Sell | 7302026 | 38.88 | 6,000 | 233,280 | 3,363,548 | Form |
| 9 | Wehrwein, Sven | Direct | Sell | 7302026 | 37.84 | 25,000 | 946,000 | 1,533,201 | Form | |
| 10 | Prange, Karen | Direct | Sell | 5222026 | 28.65 | 3,000 | 85,950 | 755,586 | Form | |
| 11 | Doraiswamy, Vinayak | Chief Scientific Officer | Direct | Sell | 5182026 | 28.13 | 5,000 | 140,650 | 2,584,444 | Form |
| 12 | Doraiswamy, Vinayak | Chief Scientific Officer | Direct | Sell | 3162026 | 29.83 | 5,000 | 149,150 | 2,889,781 | Form |
| 13 | Noznesky, Justin J | Chief Mktg & Strategy Officer | Direct | Sell | 11262025 | 37.29 | 5,166 | 192,640 | 2,938,377 | Form |
| 14 | Wehrwein, Sven | Direct | Sell | 11262025 | 38.00 | 4,967 | 188,746 | 1,306,212 | Form | |
| 15 | Wehrwein, Sven | Direct | Sell | 11262025 | 37.32 | 5,033 | 187,832 | 1,282,838 | Form | |
| 16 | Yuen, Maggie | Direct | Sell | 11252025 | 35.72 | 3,000 | 107,160 | 406,172 | Form | |
| 17 | Noznesky, Justin J | Chief Mktg & Strategy Officer | Direct | Sell | 9162025 | 36.30 | 3,000 | 108,900 | 3,047,893 | Form |
Investor Activity (13F)
Updated Sep 18, 2026Active managers (13F portfolio over $250M, at least 3 holdings) with a position over $5M that is either over 10% of their portfolio or held in a concentrated book of 50 or fewer total positions. Index/ETF, sovereign, bank, community-bank and charitable/donor-advised filers are excluded.
| Active Manager |
|---|
External Quote Links
| Y Finance | Barrons |
| TradingView | Morningstar |
| SeekingAlpha | ValueLine |
| Motley Fool | Robinhood |
| CNBC | Etrade |
| MarketWatch | Unusual Whales |
| YCharts | Perplexity Finance |
| FinViz |
Prefer one of these to Trefis? Tell us why.